根据STEP HFpEF试验,EMA建议更新Wegovy标签,以检测与肥胖相关的HFpEF. EMA recommends updating Wegovy label for obesity-related HFpEF based on STEP HFpEF trials.

欧洲药物管理局 (EMA) 建议更新诺沃诺迪斯克公司的Wegovy® (半谷胺2. 4 mg) 标签,以包括其在与肥胖相关的心力衰竭与保存喷射分数 (HFpEF) 的益处. The European Medicines Agency (EMA) has recommended updating the label for Novo Nordisk's Wegovy® (semaglutide 2.4 mg) to include its benefits for obesity-related heart failure with preserved ejection fraction (HFpEF). 这项建议是根据STEP高频高频FF试验提出的,表明病人的心衰症症状和身体功能有所改善。 This recommendation is based on STEP HFpEF trials, demonstrating improved heart failure symptoms and physical function in patients. Wegovy已经获准进行体重管理,并在心脏健康方面显示出额外的健康效益。 Wegovy is already approved for weight management and has shown additional health benefits in heart health.

September 19, 2024

17 文章